Literature DB >> 6776576

The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man.

C Thornton, C J Doré, J D Elsworth, M Herbert, G M Stern.   

Abstract

The effect of (-)-deprenyl, a rapidly acting selective monoamine oxidase (MAO) B inhibitor, on the sleep and mood of six healthy young male adults was investigated. The drug was administered double-blind in a balanced cross-over design. The dose (5-10 mg/day for 3 days) was chosen to cause complete inhibition of MAO, a process which usually takes 1-2 weeks with conventional MAO inhibitors. The inhibition was monitored by measuring platelet MAO activity and phenylethylamine excretion. Urinary phenylethylamine concentration was raised in all subjects. Subjects were unaware of any sleep disturbance due to the drug although the electroencephalogram (EEG) showed increased wakefulness. The onset of rapid-eye-movement (REM) sleep was delayed and the total amount reduced; the amount of stage 2 sleep was increased. The only effect of the drug on mood was to decrease the level of alertness prior to sleep. There was a slight but significant increase in the pre-sleep systolic blood pressure. There were no effects due to drug withdrawal.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6776576     DOI: 10.1007/bf00435308

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard.

Authors:  T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda
Journal:  Psychiatry Clin Neurosci       Date:  2001-06       Impact factor: 5.188

2.  The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors:  W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

3.  REM sleep and central monoamine oxidase inhibition.

Authors:  D J Kupfer; M B Bowers
Journal:  Psychopharmacologia       Date:  1972

4.  Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo.

Authors:  D S Robinson; W Lovenberg; H Keiser; A Sjoerdsma
Journal:  Biochem Pharmacol       Date:  1968-01       Impact factor: 5.858

5.  Mono-amine oxidase inhibitors, sleep and mood.

Authors:  M O Akindele; J I Evans; I Oswald
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1970-07

6.  Dopamine is a monoamine oxidase B substrate in man.

Authors:  V Glover; M Sandler; F Owen; G J Riley
Journal:  Nature       Date:  1977-01-06       Impact factor: 49.962

7.  On the mode of action of L-deprenyl in the human central nervous system.

Authors:  P Riederer; M B Youdim; W D Rausch; W Birkmayer; K Jellinger; D Seemann
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

8.  The possible mechanisms of action of (-)deprenyl in Parkinson's disease.

Authors:  J Knoll
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

9.  Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCl, "E-250").

Authors:  E Varga; L Tringer
Journal:  Acta Med Acad Sci Hung       Date:  1967

10.  Deprenyl in Parkinson's disease.

Authors:  A J Lees; K M Shaw; L J Kohout; G M Stern; J D Elsworth; M Sandler; M B Youdim
Journal:  Lancet       Date:  1977-10-15       Impact factor: 79.321

View more
  4 in total

Review 1.  Selegiline and Parkinson's disease. Protective and symptomatic considerations.

Authors:  L I Golbe; J W Langston; I Shoulson
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  Sleep disorders and daytime sleepiness in Parkinson's disease.

Authors:  Renee Monderer; Michael Thorpy
Journal:  Curr Neurol Neurosci Rep       Date:  2009-03       Impact factor: 5.081

3.  Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline.

Authors:  A Korn; B Wagner; E Moritz; J Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

4.  The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.

Authors:  J R Fozard; M Zreika; M Robin; M G Palfreyman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.